BioCryst Pharmaceuticals Management
Management criteria checks 3/4
BioCryst Pharmaceuticals' CEO is Jon Stonehouse, appointed in Jan 2007, has a tenure of 17.33 years. total yearly compensation is $4.78M, comprised of 13.9% salary and 86.1% bonuses, including company stock and options. directly owns 0.41% of the company’s shares, worth $4.54M. The average tenure of the management team and the board of directors is 4.2 years and 4.8 years respectively.
Key information
Jon Stonehouse
Chief executive officer
US$4.8m
Total compensation
| CEO salary percentage | 13.9% |
| CEO tenure | 17.3yrs |
| CEO ownership | 0.4% |
| Management average tenure | 4.2yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
BioCryst: Estimate-Beating Q1 But Risks Are Considerable
May 07Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price
Apr 29
BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look
Feb 27BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jan 09BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business
Jun 08BioCryst Pharmaceuticals: Working To Increase Market Presence Of Orladeyo
Oct 11BioCryst Pharmaceuticals promotes Sheridan to development chief
Sep 14BioCryst wins FDA’s Orphan Drug status for bone disorder therapy
Aug 31BioCryst to supply 10K doses of influenza drug Rapivab to US for ~$7M
Aug 25BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks
Aug 18BioCryst Pharmaceuticals Q2 2022 Earnings Preview
Aug 03BioCryst Pharmaceuticals: Waiting For Clarity
Jul 25BioCryst: A Prudent Diversification
Jun 24BioCryst: BCX9930's Hiccup Affects The Entire Company
Apr 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$209m |
| Dec 31 2023 | US$5m | US$666k | -US$227m |
| Sep 30 2023 | n/a | n/a | -US$236m |
| Jun 30 2023 | n/a | n/a | -US$243m |
| Mar 31 2023 | n/a | n/a | -US$226m |
| Dec 31 2022 | US$7m | US$640k | -US$247m |
| Sep 30 2022 | n/a | n/a | -US$193m |
| Jun 30 2022 | n/a | n/a | -US$210m |
| Mar 31 2022 | n/a | n/a | -US$194m |
| Dec 31 2021 | US$7m | US$583k | -US$184m |
| Sep 30 2021 | n/a | n/a | -US$227m |
| Jun 30 2021 | n/a | n/a | -US$214m |
| Mar 31 2021 | n/a | n/a | -US$209m |
| Dec 31 2020 | US$6m | US$567k | -US$183m |
| Sep 30 2020 | n/a | n/a | -US$125m |
| Jun 30 2020 | n/a | n/a | -US$116m |
| Mar 31 2020 | n/a | n/a | -US$115m |
| Dec 31 2019 | US$2m | US$550k | -US$109m |
| Sep 30 2019 | n/a | n/a | -US$134m |
| Jun 30 2019 | n/a | n/a | -US$126m |
| Mar 31 2019 | n/a | n/a | -US$107m |
| Dec 31 2018 | US$4m | US$550k | -US$101m |
| Sep 30 2018 | n/a | n/a | -US$93m |
| Jun 30 2018 | n/a | n/a | -US$79m |
| Mar 31 2018 | n/a | n/a | -US$77m |
| Dec 31 2017 | US$4m | US$533k | -US$66m |
Compensation vs Market: Jon's total compensation ($USD4.78M) is above average for companies of similar size in the US market ($USD3.39M).
Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.
CEO
Jon Stonehouse (62 yo)
17.3yrs
Tenure
US$4,777,778
Compensation
Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co. Ltd. since joining in January 8, 2007 and also has been its President s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 17.3yrs | US$4.78m | 0.41% $ 4.5m | |
| Senior VP | 4.1yrs | US$1.79m | 0.065% $ 709.9k | |
| Senior VP | 17.7yrs | US$1.93m | 0.087% $ 951.0k | |
| Chief Research & Development Officer | 3.2yrs | US$2.39m | 0.040% $ 443.7k | |
| Senior VP & Chief Commercial Officer | 4.3yrs | US$1.74m | 0.086% $ 947.2k | |
| Chief Communications Officer | no data | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Chief Development Officer & Interim Chief Medical Officer | 15.8yrs | US$2.66m | 0% $ 0 | |
| Chief Discovery Officer | 10.6yrs | US$2.57m | 0% $ 0 | |
| Chief Data & Insights Officer | 2.5yrs | no data | no data | |
| Chief Strategy Officer | 1.7yrs | no data | no data | |
| Chief Business Development Officer | 1.3yrs | no data | no data |
4.2yrs
Average Tenure
56yo
Average Age
Experienced Management: BCRX's management team is considered experienced (4.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 17.3yrs | US$4.78m | 0.41% $ 4.5m | |
| Independent Director | 2.8yrs | US$434.82k | 0.017% $ 187.5k | |
| Independent Director | 5.3yrs | US$446.90k | 0.023% $ 247.9k | |
| Independent Director | 4.3yrs | US$434.54k | 0.0099% $ 108.3k | |
| Independent Director | 12.6yrs | US$432.74k | 0.0062% $ 68.4k | |
| Independent Director | 5.4yrs | US$433.57k | 0.017% $ 186.8k | |
| Independent Chair | 12.3yrs | US$470.30k | 0.032% $ 346.2k | |
| Independent Director | 2.7yrs | US$424.40k | 0.0062% $ 68.4k | |
| Independent Director | 2.3yrs | US$423.15k | 0.0043% $ 47.2k | |
| Independent Director | 2.7yrs | US$422.32k | 0.0062% $ 68.4k |
4.8yrs
Average Tenure
62.5yo
Average Age
Experienced Board: BCRX's board of directors are considered experienced (4.8 years average tenure).